City

Dallas (1)

Denver (1)

Duarte (1)

Leipzig (1)

Palo Alto (1)

Rochester (1)

Seattle (1)

Stanford (1)

Torino (1)

Condition

Accelerated Phase of Disease (2)

Chronic Myelogenous Leukemia, BCR-ABL1 Positive (2)

Chronic Phase of Disease (2)

Recurrent Disease (2)

Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative (1)

Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive (1)

Chronic Myelomonocytic Leukemia (1)

Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable (1)

Overall Status

Completed (2)

Phase

phase 1/phase 2 (1)

phase 2 (1)

Sponsor

Fred Hutchinson Cancer Center (1)

National Cancer Institute (NCI) (1)

Collaborator

National Cancer Institute (NCI) (1)

Intervention

laboratory biomarker analysis (2)

cyclosporine (1)

fludarabine phosphate (1)

mycophenolate mofetil (1)

nonmyeloablative allogeneic hematopoietic stem cell transplantation (1)

peripheral blood stem cell transplantation (1)

therapeutic allogeneic lymphocytes (1)

tipifarnib (1)

total-body irradiation (1)

Study Documents

Intervention Type

drug (2)

other (2)

biological (1)

procedure (1)

radiation (1)

Funder Type

NIH (1)

Other (1)

Study Type

Interventional (2)

accelerated phase of disease

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Accelerated Phase of Disease, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1

Completed

Accelerated Phase of Disease
+4 more

Fludarabine Phosphate
+7 more

Duarte, California
+7 more

Jan 7, 2020

Accelerated Phase of Disease, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelogenous Leukemia, BCR-ABL1

Completed

Accelerated Phase of Disease
+6 more

Laboratory Biomarker Analysis
Tipifarnib

Palo Alto, California
+1 more

May 31, 2018